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one remodeling is an important physiologic process
that is required to maintain a constant bone mass.
This is achieved through a balanced activity of
bone-resorbing osteoclasts and bone-forming osteo-
blasts. In this study, we identify the high mobility group
transcription factor Sox8 as a physiologic regulator of
bone formation. 
 
Sox8
 
-deﬁcient mice display a low bone
mass phenotype that is caused by a precocious osteoblast
differentiation. Accordingly, primary osteoblasts derived
from these mice show an accelerated mineralization ex vivo
and a premature expression of osteoblast differentiation
B
 
markers. To conﬁrm the function of Sox8 as a negative
regulator of osteoblast differentiation we generated trans-
genic mice that express 
 
Sox8
 
 under the control of an
osteoblast-speciﬁc 
 
Col1a1
 
 promoter fragment. These mice
display a severely impaired bone formation that can be
explained by a strongly reduced expression of 
 
runt-
related transcription factor 2
 
, a gene encoding a tran-
scription factor required for osteoblast differentiation.
Together, these data demonstrate a novel function of
Sox8, whose tightly controlled expression is critical for
bone formation.
 
Introduction
 
Bone is a highly specialized tissue whose primary functions
are to provide mechanical support and physical protection of
soft tissues and to act as a storage system for mineral homeo-
stasis. There are two distinct types of bone that can be classified
based on their different development (Olsen et al., 2000).
Bones of the skull as well as the clavicles are formed by in-
tramembranous ossification, where mesenchymal cells directly
differentiate into bone-forming osteoblasts. In contrast, the
other skeletal elements form by endochondral ossification,
where a cartilage intermediate is subsequently replaced by
bone through the activity of osteoclasts and osteoblasts (Kro-
nenberg, 2003). Besides the growth plate the most critical
region for skeletal development and growth is the periosteal
bone collar, where the bone matrix is deposited by primordial
osteoblasts and specialized hypertrophic chondrocytes (Bianco
et al., 1998).
Once the vertebrate skeleton has reached its final size and
shape, bone is constantly remodeled, thereby providing the
possibility to adapt to changes in daily activities and to contribute
to mineral homeostasis. This remodeling process is coordinated
on several levels to achieve a balance between bone formation
by osteoblasts and bone resorption by osteoclasts, thereby
maintaining a sufficient bone mass (Amling et al., 2000). The
disturbance of this balance can lead to bone loss and osteoporosis,
one of the most prevalent degenerative diseases. Therefore, the
identification of mechanisms regulating the differentiation and
activity of bone-forming osteoblasts is an important step toward
the identification of novel therapeutic options to regain bone
mass in osteoporotic patients.
Osteoblasts differentiate from mesenchymal precursor
cells in a process requiring the coordinated activity of tran-
scription factors and other signaling proteins (Harada and
Rodan, 2003). Among these molecules, the 
 
runt
 
-related tran-
scription factor 2 (Runx2) is generally considered to be a
master regulator of osteoblast differentiation and bone formation
based on overwhelming genetic evidence (Karsenty, 1999;
Komori, 2002). First, 
 
Runx2
 
-deficient mice fail to form bone,
which is explained by a complete absence of osteoblasts
(Komori et al., 1997; Otto et al., 1997). Second, mice lacking one
allele of 
 
Runx2
 
 display a defect in intramembranous ossification
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that is reminiscent of cleidocranial dysplasia, an autosomal
dominant disorder caused by mutations of the human 
 
Runx2
 
gene (Lee et al., 1997; Mundlos et al., 1997, Otto et al., 1997).
Third, transgenic mice expressing a dominant-negative variant
of 
 
Runx2
 
 in differentiated osteoblasts display an osteopenic phe-
notype, thereby demonstrating that Runx2 is also required for
the functional activity of osteoblasts (Ducy et al., 1999). This ac-
tion of Runx2 is, at least in part, mediated through osterix (Osx),
another transcription factor required for osteoblast differentia-
tion, acting downstream of Runx2 (Nakashima et al., 2002).
Although Runx2 has an additional function in the regula-
tion of chondrocyte hypertrophy (Takeda et al., 2001), the most
important transcription factor in terms of chondrogenesis is
Sox9, because it is required for determination, proliferation, and
differentiation of mesenchymal progenitors into chondrocytes
(De Crombrugghe et al., 2001). Accordingly, endochondral
bone formation is inhibited at an early phase and does not take
place in the absence of Sox9 (Akiyama et al., 2002). Similarly,
human patients with heterozygous 
 
SOX9
 
 mutations suffer from
campomelic dysplasia, a severe skeletal malformation syn-
drome (Foster et al., 1994; Wagner et al., 1994). Sox9 belongs
to a family of high mobility group transcription factors with
close resemblance to the male sex-determining factor Sry in
their DNA-binding domain and many different functions during
mammalian development (Wegner, 1999; Bowles et al., 2000).
Among these Sox proteins, Sox9 exhibits closest similarity to
Sox8 and Sox10, and together these three proteins form the
group E of the Sox family. Sox10 has been studied extensively
and is required in derivatives of the neural crest and glial cells
of the central nervous system at various phases of development
(Herbarth et al., 1998; Southard-Smith et al., 1998; Britsch et
al., 2001; Stolt et al., 2002; J. Kim et al., 2003). In contrast,
much less is known about the physiologic role of Sox8.
Despite the widespread expression of 
 
Sox8
 
 (Pfeifer et al.,
2000; Schepers et al., 2000), 
 
Sox8
 
-deficient mice appeared
remarkably normal, exhibiting mainly a significant overall
weight reduction (Sock et al., 2001). The lack of a more severe
phenotype may be explained by the fact that in many tissues
 
Sox8
 
 is coexpressed with 
 
Sox9
 
 and 
 
Sox10
 
. Because Sox8 has
similar biochemical properties as Sox9 and Sox10 in vitro
 
,
 
 the
Sox8 deficiency is possibly compensated by the remaining pro-
duction of either of these two Sox proteins. Previously, we had
however noticed, that ossification of tarsal bones in the hind-
feet of 
 
Sox8
 
-deficient mice was disturbed (Sock et al., 2001),
arguing that Sox8 might have a previously uncharacterized role
in skeletal biology. This finding prompted us to analyze the
skeletal phenotype of 
 
Sox8
 
-deficient mice.
Here, we show that 
 
Sox8
 
-deficient mice display an os-
teopenic phenotype that is caused by an intrinsic osteoblast
differentiation defect. Primary osteoblasts derived from these
mice show an accelerated differentiation and mineralization
compared with wild-type cells, where 
 
Sox8
 
 expression ceases
upon differentiation. The fact that transgenic mice that express
 
Sox8
 
 under the control of an osteoblast-specific 
 
Col1a1
 
 pro-
moter fragment display severe defects in bone formation demon-
strates that the down-regulation of 
 
Sox8
 
 is required for osteoblast
differentiation and an essential step in bone remodeling.
 
Results
 
Osteopenia in 
 
Sox8
 
-deficient mice
 
To determine whether Sox8 has a physiologic function in skel-
etal biology, we embarked on a full characterization of the
skeletal phenotype of 
 
Sox8
 
-deficient mice. We first studied
their skeletal development and stained embryos with alcian
blue and alizarin red without finding gross abnormalities com-
pared with wild-type littermates (Fig. 1 A). To rule out subtle
defects of endochondral ossification, we histologically ana-
lyzed the hindlimbs from wild-type and 
 
Sox8
 
-deficient em-
bryos at 16.5 and 18.5 dpc, as well as from newborn mice.
Again, we did not observe significant differences between the
two groups (Fig. 1 B).
In contrast, the radiographic analysis of whole skeletons
at 6 wk old revealed that 
 
Sox8
 
-deficient mice were reduced in
size and displayed an increased radiolucency as well as a re-
duction of clavicle size (Fig. 1 C). To determine whether the
overall size reduction of the 
 
Sox8
 
-deficient mice is caused by
defects in the growth plate, we next analyzed the differentiation
of growth plate chondrocytes, where 
 
Sox8
 
 has been shown to
be expressed (Sock et al., 2001). Using in situ hybridization,
we did not observe a difference between wild-type and 
 
Sox8
 
-
deficient mice concerning the expression of 
 
Col2a1
 
, a marker
of nonhypertrophic chondrocytes, and 
 
Col10a1
 
, a marker of
hypertrophic chondrocytes (Fig. 1 D). Incorporation of BrdU
into chondrocytes of the proliferative zone also failed to reveal
a difference in the proliferation rate of growth plate chondro-
cytes between the two groups (Fig. 1 E). Histologically, the
growth plate organization and thickness was the same in wild-
 
Figure 1.
 
Analysis of endochondral and intramembranous ossification in 
 
Sox8
 
-deficient mice.
 
 (A) Staining of wild-type (WT) and 
 
Sox8
 
-deficient (
 
 
 
/
 
 
 
)
skeletons with alcian blue and alizarin red at 17.5 dpc of embryonic development. No gross abnormalities were observed in the absence of Sox8.
(B) Staining of undecalcified tibia sections with Toluidine blue and silver nitrate at 16.5 and 18.5 dpc, as well as in newborn wild-type and 
 
Sox8
 
-deficient mice.
No significant defects of endochondral ossification were observed in the absence of Sox8. (C) Radiographic analysis of skeletons from wild-type and
 
Sox8
 
-deficient mice at 6 wk old. The 
 
Sox8
 
-deficient mice are smaller, show an increased radiolucency (arrows) and display hypoplastic clavicles
(arrowheads) compared with wild-type littermates. A high power magnification of vertebral bodies is shown in the inset. (D) In situ hybridization analysis
for the expression of 
 
Col2a1
 
 and 
 
Col10a1
 
 in the growth plates from wild-type and 
 
Sox8
 
-deficient mice 2 d after birth showing normal chondrocyte differ-
entiation in the absence of Sox8. (E) Analysis of chondrocyte proliferation by BrdU-incorporation assays at 1 wk old. No significant difference in the
percentage of BrdU-positive cells was observed between the two groups. (F) Hematoxylin/eosin staining of tibial growth plates at 1 wk old. No difference
in growth plate organization and thickness was observed between the groups. P, Proliferative zone, PH, prehypertrophic zone, H, hypertrophic zone.
(G) Staining with alcian blue and alizarin red reveals a size reduction of 
 
Sox8
 
-deficient clavicles at 6 wk old. (H) 
 
 
 
CT imaging of the calvariae from 6-wk-old
wild-type and 
 
Sox8
 
-deficient mice showing hypomineralization in the absence of Sox8. The calvarial thickness is decreased in 
 
Sox8
 
-deficient mice at
6 and 20 wk old. Values represent means 
 
 
 
 SEM (
 
n 
 
  
 
6). Asterisks indicate statistically significant differences as determined by 
 
t
 
 test between the two
groups (
 
n 
 
  
 
6). **, P 
 
  
 
0.005. 
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type and 
 
Sox8
 
-deficient mice at 1 wk old (Fig. 1 F) and thereaf-
ter (Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200408013/DC1). Together, these data demonstrate that the
loss of Sox8 does not affect chondrocyte proliferation and dif-
ferentiation in the growth plate.
Therefore, it was likely that the size reduction of the
 
Sox8
 
-deficient mice is caused by defects in postnatal bone for-
mation. This possibility is underscored by the finding that
bones formed by intramembranous ossification were also af-
fected in the absence of Sox8. Besides the reduction of the
clavicle size (Fig. 1 G) we observed a hypomineralization of
the calvariae using 
 
 
 
CT analysis (Fig. 1 H). The quantification
of the calvarial thickness revealed that the absence of Sox8
leads to a 50% reduction at the age of 6 and 20 wk. This sug-
gested that 
 
Sox8
 
-deficient mice display an osteopenic pheno-
type that is caused by an impaired bone formation.
We next performed a complete histomorphometric analy-
sis of bone remodeling parameters in 
 
Sox8
 
-deficient mice and
wild-type littermates at 6 and 20 wk old. Von Kossa staining of
undecalcified sections confirmed the osteopenia in 
 
Sox8
 
-defi-
cient mice at both ages (Fig. 2, A and B). The histomorphomet-
ric analysis revealed that the trabecular bone volume in verte-
bral bodies and tibiae of 
 
Sox8
 
-deficient mice was decreased by
 
 
 
30% compared with wild-type littermates. Further analysis
demonstrated that trabecular number and trabecular thickness
were significantly decreased in 
 
Sox8
 
-deficient mice at both
ages (Fig. 2 C).
We next determined the numbers and activities of the two
cell types involved in bone remodeling. The quantification
of cuboidal osteoblasts demonstrated that their number was
decreased by 70% in 
 
Sox8
 
-deficient mice compared with wild-
type littermates, thereby resulting in a significantly decreased
bone formation rate (Fig. 2 D). The number of bone-resorbing
osteoclasts was slightly decreased in 
 
Sox8
 
-deficient mice at 20
wk old, but not at 6 wk old. In contrast, we did not observe a
significant difference compared with wild-type littermates at
both ages when we quantified the concentration of urinary col-
lagen degradation products as a measure of bone resorption
(Fig. 2 E). Together, these data demonstrate that the lack of
Sox8 in mice causes an osteopenic phenotype that can be ex-
plained by an impaired osteoblast differentiation, thereby re-
sulting in a decreased bone formation.
 
Accelerated osteoblast differentiation in 
the absence of Sox8
 
To determine whether the decreased bone formation of 
 
Sox8
 
-
deficient mice is caused by an intrinsic osteoblast differentia-
tion defect, we next studied the behavior of wild-type and
 
Sox8
 
-deficient primary calvarial osteoblasts ex vivo. We first
analyzed 
 
Sox8
 
 expression in these cells by Northern blotting
and found a strong expression in nondifferentiated wild-type
cultures. Importantly, this expression was completely abolished
5 and 10 d after the addition of ascorbic acid and 
 
 
 
-glycero-
phosphate, two agents leading to terminal osteoblast differenti-
ation and mineralization ex vivo (Fig. 3 A). We next deter-
mined the proliferation of wild-type and 
 
Sox8
 
-deficient primary
calvarial osteoblasts. Using a BrdU incorporation assay we
found that the proliferation rate of 
 
Sox8
 
-deficient cells was
strongly reduced compared with wild-type cells, even before
osteoblast differentiation was induced (Fig. 3 B). To analyze
Figure 2. Osteopenia in Sox8-deficient mice.
(A) Von Kossa staining of undecalcified verte-
bral sections and quantification of the trabecular
bone volume (BV/TV, bone volume per tissue
volume) reveals an osteopenic phenotype in
Sox8-deficient mice at 6 wk old. (B) The same
was observed in sections from vertebral bodies
and tibiae at 20 wk old. (C) Histomorphometric
quantification shows that trabecular number
(Tb.N) and trabecular thickness (Tb.Th) are
significantly decreased in Sox8-deficient mice
(gray bars) compared with wild-type litter-
mates (white bars) at both ages. (D) Histomor-
phometric quantification of trabecular bone
formation parameters. The number of cuboidal
osteoblasts (Ob.N/BPm, osteoblast number
per bone perimeter) is strongly decreased in
Sox8-deficient mice compared with wild-type
littermates. This results in a significant reduction
of the bone formation rate as determined by
dynamic histomorphometry after dual calcein
injection. (E) Quantification of bone resorption
parameters. Although the numbers of osteo-
clasts (N.Oc/BPm, osteoclast number per bone
perimeter) are decreased in Sox8-deficient
mice at 20 wk old, there is no significant
change in bone resorption as determined
by measuring the urinary deoxypyridinoline
(Dpd) cross-links. Values represent means  
SEM. Asterisks indicate statistically signifi-
cant differences as determined by t test be-
tween the two groups (n   6). *, P   0.05;
**, P   0.005. 
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osteoblast differentiation we performed Von Kossa staining of
the mineralized matrix from wild-type and 
 
Sox8
 
-deficient cells
formed before (d0) as well as 5 and 10 d after the addition of
ascorbic acid and 
 
 
 
-glycerophosphate. Unexpectedly, we ob-
served an accelerated mineralization of 
 
Sox8
 
-deficient cells. In
contrast to wild-type cultures, mineralized nodules were already
detectable after 5 d of differentiation. After 10 d the mineralization
was still much more pronounced (Fig. 3 C).
To correlate these results to the situation in vivo, we first
analyzed 
 
Sox8
 
 expression in osteoblasts. Because the targeted
deletion of the 
 
Sox8
 
 gene had introduced a 
 
lacZ
 
 reporter gene
whose expression faithfully mimicked that of 
 
Sox8
 
, we per-
formed X-Gal staining of bone sections from 
 
Sox8
 
-deficient
mice. In addition to the expression in growth plate cartilage, we
also detected staining in the primary spongiosa (Fig. 3 D). At
higher magnification we observed 
 
lacZ
 
-positive groups of cells
at the bone surface suggesting expression in osteoblasts that
typically act in teams when they form new bone (Parfitt, 1983).
To analyze osteoblast proliferation in vivo we performed BrdU
incorporation assays in the calvariae from wild-type and 
 
Sox8
 
-
deficient mice. Thereby we found that the percentage of prolif-
erating cells was decreased by 65% in 
 
Sox8
 
-deficient mice
compared with wild-type littermates (Fig. 3 E). Having verified
the decreased proliferation of osteoblast precursor cells in
Sox8-deficient mice, we next analyzed their differentiation on
trabecular bone surfaces. Toluidine blue staining revealed a
striking morphologic difference between wild-type and Sox8-
deficient mice at the sites of bone formation. Although in wild-
type mice the bone-forming units at the trabecular bone surface
are comprised of large teams of osteoblasts, we observed that
the number of osteoblasts within these teams was decreased by
70% in Sox8-deficient mice (Fig. 3 F). This observation was
corroborated by the finding that the length of labeled surfaces
after dual calcein injection was significantly decreased in Sox8-
deficient mice compared with wild-type littermates (Fig. 3 G).
Together, these observations suggest that loss of Sox8 results
in premature osteoblast differentiation at the expense of pro-
liferation, thereby reducing the number of active osteoblasts
within the bone-forming units.
We next analyzed the expression of osteoblast differ-
entiation markers in wild-type and Sox8-deficient primary
osteoblasts by RT-PCR. In wild-type cultures expression of
Figure 3. Decreased proliferation and acceler-
ated differentiation of Sox8-deficient osteoblasts.
(A) Analysis of Sox8 expression in primary
calvarial osteoblast cultures. Northern blot
expression analysis shows that Sox8 is ex-
pressed in nondifferentiated wild-type calvarial
osteoblast cultures (d0), but not in the same
cultures 5 and 10 d (d5 and d10) after the addi-
tion of ascorbic acid and  -glycerophosphate.
(B) Analysis of osteoblast proliferation. A BrdU-
incorporation assay with primary osteoblasts
from wild-type (white bars) and Sox8-deficient
(gray bars) mice reveals a strong reduction of
osteoblast  proliferation in the absence of
Sox8, occurring before ascorbic acid and
 -glycerophosphate were added to the culture
medium (d0). (C) Analysis of ECM mineraliza-
tion. Von Kossa staining reveals an accelerated
mineralization of Sox8-deficient primary osteo-
blast cultures compared with wild-type cultures.
n.d., not detectable. (D) X-Gal staining of tibia
sections from Sox8-deficient mice at 1 wk old
reveals LacZ expression in the growth plate,
but  also in cells of the primary spongiosa
(arrowheads). Higher magnification reveals
expression in groups of cells (indicated by the
dotted red lines) at the bone surface which is
characteristic of osteoblasts. (E) Analysis of
osteoblast proliferation in vivo by BrdU-incor-
poration assays at 1 wk old. The percentage
of BrdU-positive cells in calvarial sections is
significantly decreased in Sox8-deficient mice
compared with wild-type littermates. Note the
flattened appearance of Sox8-deficient osteo-
blasts compared with wild-type controls, sug-
gesting premature differentiation. (F) Toluidine
blue staining of undecalcified vertebral bone
sections shows that the teams of bone-forming
osteoblasts (indicated by the dotted red lines)
are shorter in Sox8-deficient mice. Quantifica-
tion of the average numbers of osteoblasts
within these bone-forming units (N.Ob/BFU)
reveals a significant reduction in the absence
of Sox8. (G) Fluorescent micrographs showing the calcein-labeled surfaces representing newly formed bone. The length of these surfaces is significantly
decreased in Sox8-deficient mice. Values represent means   SEM. Asterisks indicate statistically significant differences as determined by t test between the
two groups (n   6). **, P   0.005.JCB • VOLUME 168 • NUMBER 6 • 2005 904
tissue-nonspecific alkaline phosphatase (Tnsalp), osteocalcin
(Osc), bone sialoprotein (Bsp), phosphate-regulating gene
with homologies to endopeptidases located on the X-chromo-
some (Phex), Runx2 and Osx was observed only 5 and 10 d
after the addition of ascorbic acid and  -glycerophosphate
(Fig. 4 A). In Sox8-deficient cells however, we observed a
different expression pattern for all of these genes except Osc.
Whereas Tnsalp was prematurely down-regulated in the ab-
sence of Sox8, Bsp, and Phex, two genes associated with
ECM mineralization, were expressed in Sox8-deficient cells
even without the addition of ascorbic acid and  -glycero-
phosphate (Fig. 4 A). A premature expression in Sox8-defi-
cient cells was also observed for Runx2 and Osx, two genes
encoding transcription factors required for osteoblast differ-
entiation. In contrast, we did not observe changes in the ex-
pression pattern of low density lipoprotein receptor-related
protein 5 (Lrp5), a gene that was recently identified to play a
major role in bone formation in a Runx2-independent manner
(Kato et al., 2002).
Figure 4. Premature expression of osteoblast differentiation markers in
Sox8-deficient osteoblasts. (A) RT-PCR expression analysis of primary
osteoblast cultures from wild-type (WT) and Sox8-deficient ( / ) mice at
d0, d5, and d10 of differentiation. Note the premature expression of Bsp,
Phex, Runx2, and Osx in Sox8-deficient cultures. Tnsalp (tissue nonspecific
alkaline phosphatase), Osc (osteocalcin), Bsp (bone sialoprotein), Phex
(phosphate-regulating gene with homologies to endopeptidases located
on the X-chromosome), Runx2 (runt-related transcription factor 2), Osx
(osterix), Lrp5 (low density lipoprotein receptor-related protein 5), Gapdh
(Glycerinaldehydephosphate dehydrogenase). (B) Analysis of Runx2
DNA-binding activity. An electrophoretic mobility shift assay using the
Runx2-binding site (OSE-2; Ducy et al., 1997) reveals the presence of
Runx2 in nuclear extracts from nondifferentiated Sox8-deficient osteo-
blasts, but not from wild-type osteoblasts (d0). Binding was not observed
with a mutated binding site (mutOSE-2) or in the presence of an anti–
Runx2-antibody. (C) Analysis of osteoblast differentiation markers in vivo.
A Northern blot expression analysis using calvaria and femur RNA from
wild-type and Sox8-deficient mice at 6 wk old reveals an elevated expres-
sion of Osc, Bsp, Phex, and Runx2 in the absence of Sox8.
Figure 5. Generation and skeletal analysis of Col1a1-Sox8 transgenic mice.
(A) Schematic presentation of the DNA construct used for microinjection.
Transgenic mice contain the Sox8-encoding ORF under the control of an
osteoblast-specific Col1a1 promoter fragment. The location of the primers
used for the transgene-specific expression analysis is indicated in red.
(B) Analysis of transgene expression. RT-PCR expression analysis using
transgene-specific primers reveals expression in bone and calvaria, as
well as in primary osteoblasts at all stages of differentiation. (C) Staining
of skeletons from newborn wild-type (WT) and Col1a1-Sox8 transgenic
(TG) mice with alcian blue and alizarin red. Skeletal elements of trans-
genic mice are reduced in size and staining intensity (arrows). Additionally,
their clavicles and calvariae are hypomineralized (arrowheads).REGULATION OF OSTEOBLAST DIFFERENTIATION BY SOX8 • SCHMIDT ET AL. 905
Premature Runx2 expression in Sox8-deficient osteoblasts
was also confirmed on the protein level using an electro-
phoretic mobility shift assay. The complex of Runx2 and OSE-2,
an oligonucleotide containing the Runx2 binding site, was only
observed after 5 d of differentiation in nuclear extracts from
wild-type cells, whereas it was already present before the addi-
tion of ascorbic acid and  -glycerophosphate (d0) in nuclear
extracts from Sox8-deficient cultures (Fig. 4 B). This complex
was specific for Runx2, because it was not observed when a
mutated OSE2 oligonucleotide was used, and because it disap-
peared when a Runx2-specific antibody was added to the bind-
ing reaction (Fig. 4 B).
To further confirm the premature differentiation of Sox8-
deficient osteoblasts in vivo, we performed a Northern blot
expression analysis using RNA from calvaria and femur of
wild-type and Sox8-deficient mice at 6 wk old (Fig. 4 C).
Thereby, we found an increased expression of Bsp, Phex, and
Runx2, which is consistent with the RT-PCR expression analy-
sis described above. Together, these data suggested that Sox8
is a negative regulator of osteoblast differentiation, potentially
acting through Runx2.
Impaired bone formation in Col1a1-Sox8 
transgenic mice
The fact that Sox8 expression is down-regulated upon differen-
tiation of wild-type osteoblasts raised the hypothesis that this
down-regulation is a prerequisite for osteoblast differentiation.
To interfere with Sox8 down-regulation in osteoblasts we gen-
erated transgenic mice that express Sox8 under the control of an
osteoblast-specific Col1a1 promoter fragment that is active in
osteoblast precursor cells and maintains its activity in differen-
tiated osteoblasts (Rossert et al., 1995, 1996). The transgene
consisted of the complete Sox8 ORF placed under the control
of the 2.3-kb osteoblast-specific Col1a1 promoter fragment
(Fig. 5 A). Four transgenic founders with similar phenotype and
transgene expression were obtained. Three of them were used
to generate transgenic mouse lines (Fig. S2, available at http://
www.jcb.org/cgi/content/full/jcb.200408013/DC1). The fourth
had to be killed at 10 d old because of spontaneous fracture. Ex-
pression analysis of the transgene using RT-PCR confirmed its
bone-specific expression, as well as the expected lack of down-
regulation during osteoblast differentiation (Fig. 5 B).
For the phenotypic analysis of the Col1a1-Sox8 trans-
genic mice we first stained skeletons of newborn mice with
alcian blue and alizarin red. Compared with wild-type litter-
mates the Col1a1-Sox8 transgenic mice displayed a generalized
weaker staining with alizarin red as well as a size reduction of
most skeletal elements (Fig. 5 C). Intramembranous ossifica-
tion was also affected, because we observed a severe hypomin-
eralization of the calvariae and clavicles of the transgenic mice.
Because this phenotype did not lead to postnatal lethality,
we next analyzed wild-type and transgenic mice at 2 wk old.
Using contact radiography we observed an increased radiolu-
cency in transgenic mice demonstrating a low bone mass pheno-
type (Fig. 6 A). Additionally, we found a size reduction of all
skeletal elements compared with wild-type littermates, including
the clavicles. The severe hypomineralization of calvariae that
Figure 6. Bone phenotype of Col1a1-Sox8 transgenic mice. (A) Radio-
graphic analysis of skeletons from wild-type and Col1a1-Sox8 transgenic
mice at 2 wk old. Transgenic mice are smaller, display increased radiolu-
cency compared with wild-type littermates (arrows) and have hypoplastic
clavicles (arrowheads). (B)  CT imaging reveals that the Col1a1-Sox8
transgenic mice have severe defects in calvarial bone formation and
fontanelle closure. (C) Histological analysis of vertebral bodies from wild-
type and transgenic mice at 2 wk (top) and 10 wk (bottom) old. Von Kossa
staining of undecalcified sections reveals a low bone mass phenotype in
Col1a1-Sox8 transgenic mice. Histomorphometric quantification shows
that the trabecular bone volume (BV/TV) is significantly reduced in trans-
genic mice at both ages. Values represent means   SEM. Asterisks indi-
cate statistically significant differences between the two groups (n   5).
**, P   0.005.JCB • VOLUME 168 • NUMBER 6 • 2005 906
the production of type I collagen was strongly decreased in
transgenic mice (Fig. 7 C). Because the transgenic expression
of Sox8 is driven by the promoter of this gene, we speculated
that Sox8 expression in the transgenic mice may be down-regu-
lated over time, thereby preventing a more severe phenotype.
This was confirmed by Northern blot expression analysis using
calvarial RNA from wild-type and transgenic mice at birth, 2
and 10 wk old. Whereas the expression level of the transgene
(that could be separated from the endogenous mRNA based on
the reduced size) was initially approximately five times higher
than the endogenous expression level, we observed a strong de-
crease of transgene expression at 10 wk old (Fig. 7 D).
We next analyzed whether the disturbed cortical bone
formation in the Col1a1-Sox8 transgenic mice leads to a de-
creased biomechanical stability. Cross-sectional  CT scans of
the femora confirmed the cortical porosity in transgenic mice at
2 wk old. When the stability of these femora was analyzed in
three-point–bending assays, the force required to cause bone
failure was significantly decreased in transgenic mice (Fig. 7 E).
This reduced biomechanical stability is also relevant in vivo,
because one founder animal displayed a spontaneous fracture
of the humerus. This was observed by contact radiography and
histologically confirmed by Mallory staining to verify callus
was still prominent in the transgenic mice at 2 wk old was further
visualized by  CT imaging (Fig. 6 B). Histomorphometric analy-
sis of vertebral sections demonstrated that the trabecular bone vol-
ume in transgenic mice was reduced by 40% at 2 wk old and by
30% at 10 wk old compared with wild-type littermates (Fig. 6 C).
The phenotype of the Col1a1-Sox8 transgenic mice was
especially pronounced in cortical bone. In fact, Von Kossa
staining of undecalcified tibia sections revealed an incomplete
cortical bone formation in Col1a1-Sox8 transgenic mice at 2
wk old (Fig. 7 A). Toluidine blue staining showed that in wild-
type mice cortical bone was correctly organized with several
osteocytes of flattened appearance and large teams of osteo-
blasts forming new bone. In contrast, the cortical bone matrix
of transgenic mice was disorganized, and osteoblast differenti-
ation was obviously impaired. Therefore, histomorphometric
quantification of osteoblast indices was not possible in Col1a1-
Sox8 transgenic mice at that age, because bone-forming cells
with the characteristic cuboidal appearance were not detectable
(Fig. 7 A). At 10 wk old this phenotype was still present, albeit
less severe. Osteoblasts were now quantifiable, but their num-
ber was significantly reduced by 45% (Fig. 7 B).
One possible reason for the partial recovery of the
Col1a1-Sox8 transgenic mice came from the observation that
Figure 7. Increased cortical porosity in
Col1a1-Sox8 transgenic mice. (A) Von Kossa
staining of undecalcified tibia sections from
wild-type and Col1a1-Sox8 transgenic mice at
2 wk old shows that transgenic mice display
extensive cortical porosity. Toluidine blue
staining reveals a severely impaired bone for-
mation in Col1a1-Sox8 transgenic mice. Note
that the typical morphology of osteoblasts
(located above the dotted red line) and osteo-
cytes (arrowheads) is not observed in trans-
genic mice. Quantification of osteoblast
number was not possible in transgenic mice,
because they did not contain the characteristic
cuboidal osteoblasts, in contrast to wild-type
littermates. (B) Von Kossa and Toluidine blue
staining of undecalcified tibia sections from
wild-type and Col1a1-Sox8 transgenic mice at
10 wk old reveals a partial recovery from the
severe phenotype, although the number of
osteoblasts is still significantly reduced in the
transgenic mice. (C) Immunohistochemistry us-
ing an antibody against type I collagen shows
that the amount of this protein is largely reduced
in cortical bone of transgenic mice at 2 wk old.
(D) Northern blot expression analysis using
RNA from calvariae of wild-type and Col1a1-
Sox8 transgenic mice at different ages reveals
that the expression of the transgene (arrow-
head) is strongly down-regulated over time
compared with the endogenous Sox8 expres-
sion (arrow). (E) Cross-sectional  CT scans
from femora of wild-type (WT) and Col1a1-
Sox8 transgenic (TG) mice confirming the in-
creased cortical porosity in transgenic mice at
2 wk old. Force to failure as determined by
three-point bending assays is significantly
reduced in transgenic femora indicating de-
creased biomechanical stability. (F) A sponta-
neous fracture of the humerus (white arrow) was observed by contact radiography in a Col1a1-Sox8 transgenic founder (left). Mallory staining of an
undecalcified section (right) shows that callus formation occurred at the fracture site (black arrow). Values represent means   SEM. Asterisks indicate a
statistically significant difference between the two groups (n   5). *, P   0.05; **, P   0.005.REGULATION OF OSTEOBLAST DIFFERENTIATION BY SOX8 • SCHMIDT ET AL. 907
formation (Fig. 7 F). Together, these data demonstrate that
Col1a1-Sox8 transgenic mice display a severe osteoporosis that
is caused by an impaired bone formation.
Reduced expression of Runx2 in 
osteoblasts from Col1a1-Sox8 
transgenic mice
To confirm that the phenotype of the Col1a1-Sox8 transgenic
mice is caused by an intrinsic osteoblast differentiation defect we
analyzed the behavior of primary calvarial osteoblasts from
transgenic mice and wild-type littermates. In contrast to wild-
type cultures, no mineralized bone nodules were observed after
10 d of differentiation in transgenic cultures. After 20 d only few
areas were mineralized in transgenic cultures, whereas wild-type
cultures displayed many mineralized nodules (Fig. 8 A). We next
performed an RT-PCR expression analysis for osteoblast differ-
entiation markers. In contrast to the Sox8-deficient cultures, we
observed a delayed and reduced expression of Osc, Bsp, Phex,
Runx2, and Col1a1 compared with wild-type cultures, whereas
Lrp5 expression was not significantly changed (Fig. 8 B). Again,
these results were confirmed in vivo by Northern blot expression
analysis using RNA from calvaria and femur of Col1a1-Sox8
transgenic mice and wild-type littermates at 2 wk old (Fig. 8 C).
We further performed an electrophoretic mobility shift
assay to analyze the presence of Runx2 in wild-type and trans-
genic osteoblast cultures on the protein level. In nuclear ex-
tracts from wild-type cells the complex of Runx2 and the OSE-2
oligonucleotide was present after 5 and 10 d of differentiation
(Fig. 8 D). Again, the specificity of this complex was con-
firmed by its absence using a mutated OSE2 oligonucleotide
or a Runx2-specific antibody. Most importantly however, no
complex formation was detectable when nuclear extracts from
transgenic cells were used (Fig. 8 D). To analyze whether this
finding is also relevant in vivo, we performed immunohis-
tochemistry using a Runx2-specific antibody on tibia sections
from wild-type and Col1a1-Sox8 transgenic mice. Whereas we
Figure 8. Decreased  Runx2 expression in
Col1a1-Sox8 transgenic mice. (A) Von Kossa
staining of primary osteoblast cultures from
wild-type and Col1a1-Sox8 transgenic mice
after 0, 10, and 20 d of incubation with
ascorbic acid and  -glycerophosphate. Miner-
alization of the transgenic cultures is delayed
and reduced compared with wild-type cultures.
(B)  RT-PCR expression analysis of primary
osteoblast cultures from wild-type and Col1a1-
Sox8 transgenic mice at d0, d10, and d20 of
differentiation. Note the decreased expression
of  Col1a1, Osc,  Bsp, Phex, and Runx2 in
transgenic cultures. (C) A Northern blot ex-
pression analysis using calvaria and femur
RNA from wild-type and Col1a1-Sox8 trans-
genic mice at 2 wk old reveals a reduced
expression of Col1a1, Osc, Bsp, Phex, and
Runx2 in transgenic bones. (D) An electro-
phoretic mobility shift assay using the Runx2-
binding site (OSE-2) reveals the presence of
Runx2 in nuclear extracts from differentiating
wild-type cells (d5 and d10), but not in cells
derived from transgenic mice. This binding
was not observed with a mutated binding site
(mutOSE-2) or in the presence of an anti–
Runx2-antibody. (E) Analysis of tibia sections
from wild-type and Col1a1-Sox8 transgenic
mice at 2 wk old. Von Kossa staining shows
the osteoporotic phenotype in the primary
spongiosa of transgenic mice (top). Immu-
nohistochemistry using an antibody against
Runx2 reveals that the expression of Runx2 is
down-regulated in Col1a1-Sox8 transgenic
mice (middle). The counter-staining with DAPI
is shown below. (F) Schematic presentation
explaining the phenotypes of both mouse
models and illustrating the deduced role of
Sox8 as a negative regulator of osteoblast dif-
ferentiation. In osteoblast precursor cells the
presence of Sox8 limits the amount of Runx2
expression keeping the cells in a proliferative
state. In differentiated osteoblasts Sox8 is not
expressed, and Runx2 can activate the osteo-
genic cascade leading to bone formation.JCB • VOLUME 168 • NUMBER 6 • 2005 908
found strong and specific staining of wild-type sections in the
primary spongiosa, such a staining was barely detectable in
Col1a1-Sox8 transgenic mice (Fig. 8 E). Together, these results
suggest that Sox8 limits Runx2 expression in osteoblast precur-
sor cells, and that the down-regulation of Sox8 is required to
allow their differentiation (Fig. 8 F).
Discussion
Several transcription factors have been demonstrated to play
crucial roles in cell-specific differentiation processes. These in-
clude Sox9 and Sox10, two related members of the Sox-family,
that serve important functions in chondrogenesis and gliogene-
sis (Britsch et al., 2001; De Crombrugghe et al., 2001; Ak-
iyama et al., 2002; Stolt et al., 2002). In this study we describe
a novel function for Sox8, the third member of group E of the
Sox family, as a negative regulator of osteoblast differentia-
tion. This is underscored by several findings. First, Sox8-defi-
cient mice display an osteopenic phenotype that is caused by a
precocious osteoblast differentiation. Second, Sox8-deficient
primary osteoblasts differentiate earlier than wild-type cells,
where  Sox8 expression ceases upon differentiation. Third,
Col1a1-Sox8 transgenic mice that retain Sox8 expression in
differentiated osteoblasts display an osteoporotic phenotype
caused by a severely impaired bone formation. Together, these
data demonstrate that Sox8 is a physiological regulator of bone
formation whose expression needs to be tightly controlled dur-
ing the osteoblast differentiation process. Obviously, this is the
first function of Sox8 that cannot be compensated by other
members of the Sox family (Fig. S3, available at http://
www.jcb.org/cgi/content/full/jcb.200408013/DC1). In contrast,
we did not find any defects of growth plate chondrogenesis in
the absence of Sox8, suggesting that the size reduction of the
Sox8-deficient mice is a result of impaired bone formation.
This is consistent with a contribution of bone formation to skel-
etal growth, as it has been shown for example in a mouse
model of osteoblast ablation (Corral et al., 1998).
Bone formation through osteoblasts is controlled on dif-
ferent levels (Harada and Rodan, 2003). Whereas endocrine
and neuronal mechanisms are important to regulate the func-
tional activity of osteoblasts, at least two transcription factors,
Runx2 and Osx, are required for the differentiation of mesen-
chymal precursor cells into osteoblasts (Ducy et al., 2000; Ko-
mori, 2002; Nakashima et al., 2002). Because Osx is not ex-
pressed in the absence of Runx2, the latter one is generally
considered to be a master regulator of osteoblast differentia-
tion. Runx2 activates the expression of most genes associated
with osteoblast differentiation and function, and its deficiency
in mice results in a complete lack of bone formation (Ducy et
al., 1997; Komori et al., 1997). Haploinsufficiency of Runx2
leads to cleidocranial dysplasia, a disorder characterized by de-
fects in endochondral and intramembranous bone formation in-
cluding short stature, open fontanelles, and hypoplastic clavi-
cles (Lee et al., 1997; Mundlos et al., 1997; Otto et al., 1997).
Given the important role of Runx2 in osteoblast differentiation,
it is not surprising that its expression needs to be tightly regu-
lated, which is underscored by the phenotype of transgenic
mice that overexpress Runx2 under the control of the Col1a1
promoter. Unexpectedly, these mice displayed an osteopenia
associated with spontaneous fractures (Liu et al., 2001; Geof-
froy et al., 2002), thereby demonstrating that the expression
level of Runx2 needs to be limited to allow a coordinated osteo-
blast differentiation process.
The data presented in this manuscript provide evidence that
Sox8 regulates osteoblast differentiation in a Runx2-dependent
manner. In fact, the accelerated differentiation and mineraliza-
tion of Sox8-deficient primary osteoblasts may be explained by
the premature expression of Runx2 in these cells. Likewise, the
reduced proliferation of the Sox8-deficient cells can be explained
by the same mechanism, because Runx2 has recently been dem-
onstrated to trigger the exit of preosteoblasts from the cell cycle
(Pratap et al., 2003). Furthermore, the severe phenotype of the
Col1a1-Sox8 transgenic mice is reminiscent of cleidocranial dys-
plasia, because we observed a size reduction of all skeletal ele-
ments including the clavicles as well as the characteristic failure
of fontanelle closure. Again, this phenotype can be well ex-
plained by the strong down-regulation of Runx2 in these mice.
At least two other transcription factors, Twist and Stat1,
have been demonstrated to attenuate Runx2-action in vivo (S.
Kim et al., 2003; Bialek et al., 2004). Whereas Twist is re-
quired to prevent a premature Runx2-dependent osteogenesis
during skeletal development, the function of Stat1 is more im-
portant in postnatal bone remodeling. In both cases the mecha-
nism of action is posttranscriptional. Whereas the physical in-
teraction of Twist and Runx2 decreases the DNA-binding
activity of the latter one, the interaction with Stat-1 prevents
the nuclear localization of Runx2 (S. Kim et al., 2003; Bialek et
al., 2004). In this study, we have identified Sox8 as another
molecule that exerts its inhibitory influence on osteoblast dif-
ferentiation in a Runx2-dependent manner. As is the case for
Stat1, this function is more important postnatally where Sox8 is
required to assure a coordinated osteoblast differentiation pro-
cess during bone remodeling. In contrast to Twist and Stat1
however, Sox8 acts on the transcriptional level, because the ex-
pression of Runx2 is elevated in nondifferentiated primary os-
teoblasts lacking Sox8. Therefore, it is possible that Sox8 is a
direct regulator of Runx2 promoter activity, although such a
mechanism needs to be established by future experiments. The
same is the case for the identification of molecular mechanisms
regulating  Sox8 expression during osteoblast differentiation.
One possibility is that Sox8 is under the control of BMP signal-
ing, because all group E Sox family members have been shown
to be induced after implantation of a BMP-7 bead at the tip of
the digits of chicken embryos (Chimal-Monroy et al., 2003).
Regardless of these open questions, the analyses of both
mouse models described in this manuscript demonstrate that
Sox8 is an important transcriptional regulator of osteoblast dif-
ferentiation. Through its expression in osteoblast precursor
cells Sox8 inhibits their terminal differentiation and keeps
them in the proliferative stage. Upon differentiation, Sox8 ex-
pression is down-regulated, which is required for an elevation
of Runx2 expression, consequently leading to the initiation of
an osteogenic cascade ensuring bone matrix deposition and
mineralization by the differentiated osteoblasts.REGULATION OF OSTEOBLAST DIFFERENTIATION BY SOX8 • SCHMIDT ET AL. 909
Materials and methods
Mice
Sox8-deficient mice and wild-type littermates were kept and genotyped as
described previously (Sock et al., 2001). To rule out genetic background
variations, we only analyzed mice that were backcrossed at least six times
with C57Bl/6 mice. Col1a1-Sox8 transgenic mice were obtained by in-
jecting the transgene into the pronucleus of fertilized oocytes from C57Bl/6
mice according to standard procedures (Bonnerot and Nicolas, 1993). A
plasmid containing the Col1a1 promoter was provided by B. de Crom-
brugghe (M.D. Anderson Cancer Center, Houston, TX). The plasmid con-
taining the  -globin-intron and growth hormone poly(A) was received from
M. Blessing (Universität Leipzig, Leipzig, Germany). For details on the
construct, genotyping and expression analysis, see Online supplemental
material.
Skeletal analysis
For skeletal preparations newborn mice were dissected and fixed over-
night in 95% ethanol. Staining with alcian blue and alizarin red was per-
formed using standard protocols (McLeod, 1980). For radiographic and
histologic analysis mice were killed, internal organs were removed and the
whole skeletons were fixed in 3.7% PBS-buffered formaldehyde for 18 h at
4 C. The skeletons were analyzed by contact radiography using a Fax-
itron Xray cabinet (Faxitron Xray Corp.). For three-dimensional visualiza-
tion the calvariae were scanned (40 kV/114  A) in a  CT 40 (Scanco
Medical) at a resolution of 12  m. For the assessment of the cortical poros-
ity, femora were scanned at the midshaft at a resolution of 10  m. The
raw data were manually segmented and analyzed with the  CT Evalua-
tion Program V4.4A (Scanco Medical). For visualization, the segmented
data were imported and displayed in  CT Ray V3.0 (Scanco Medical). Af-
ter fixation the skeletons were incubated in 70% ethanol for 24 h. The lum-
bar vertebral bodies (L3–L5) and one tibia of each mouse were thereafter
dehydrated in ascending alcohol concentrations and embedded in methyl-
metacrylate as described previously (Amling et al., 1999). For details on
bone histology and histomorphometry, see Online supplemental material.
Image acquisition
Images were acquired using a Axioskop2 microscope (Carl Zeiss Micro-
Imaging Inc.) with the Zeiss Plan Neofluar objective lenses: 1.25 /
0.035; 2.5 /0.075; 10 /0.3; 20 /0.5; 40 /0.75. No immersion
fluid was used. Pictures were taken at RT with a Zeiss Axiocam and Zeiss
Axiovision Software V3.1. For white balancing and adjustment of bright-
ness and contrast, Adobe Photoshop 7.0 was used.
In situ hybridization, BrdU labeling, X-Gal staining, and 
immunohistochemistry
In situ hybridization was performed according to standard procedures on
14- m-thick sections using digoxigenin-labeled antisense riboprobes cor-
responding to the 3 -untranslated region of the Col2a1-cDNA and the
third exon of the ColXa1 gene. For BrdU labeling, 1-wk-old mice were in-
jected with 100  g BrdU per gram of body weight 2 h before dissection.
Incorporated BrdU was detected by immunohistochemistry using a mono-
clonal anti-BrdU antibody obtained from DakoCytomation according to
the manufacturer’s instructions. Detection of  -galactosidase activity was
performed following standard protocols (Hogan et al., 1994). In brief, tis-
sue specimens were fixed in 1% PBS-buffered PFA for 2 d. For detection of
 -galactosidase activity, sections were covered with X-Gal staining solu-
tion and incubated at 37 C until blue precipitates were detectable. Immu-
nohistochemistry was performed on 14- m cryotome sections using spe-
cific antibodies against type I collagen (Novacostra) and Runx2 (Santa
Cruz Biotechnology, Inc.) as recommended by the manufacturer. Second-
ary antibodies conjugated to Cy3 immunofluorescent dye (Dianova) were
used for detection.
Analysis of primary osteoblast differentiation
Primary osteoblasts were obtained by sequential collagenase digestion of
calvariae from 3-d-old mice as described previously (Ducy et al., 2000).
Osteoblast differentiation was induced at 80% confluency in  -MEM con-
taining 10% FBS, 50  g/ml ascorbic acid, and 10 mM  -glycerophos-
phate. Total RNA was extracted using the TRIzol reagent (Invitrogen) im-
mediately before differentiation (d0), as well as 5 and 10 or 20 d
thereafter (d5, d10, d20). Northern blot analysis was performed accord-
ing to standard protocols with the cDNAs encoding Sox8 and Gapdh as
probes. BrdU incorporation assays were performed using the Cell Prolifer-
ation ELISA Biotrak system obtained from Amersham Biosciences accord-
ing to the manufacturer’s instructions. Mineralization of the cultures was
analyzed using Von Kossa staining as described previously (Ducy et al.,
2000). The percentage of the mineralized area was quantified using
computer aided image analysis (Image tool V2.0; University of Texas
Health Science Center, San Antonio, TX). For details on the RT-PCR ex-
pression analysis and the electrophoretic mobility shift assays, see Online
supplemental material.
Online supplemental material
Fig. S1 shows the histologic analysis of the growth plates from wild-type
and Sox8-deficient mice at 1 and 6 wk old. Fig. S2 shows a comparison
of transgene expression and phenotypes for the offspring derived from the
three different founders carrying the Col1a1-Sox8 transgene. Fig. S3
shows a Northern blot expression analysis for Sox9 and Sox10 in wild-
type and Sox8-deficient osteoblasts and bones. Further comments on the
data can be found in the legends. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200408013/DC1.
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